Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Arbutus Biopharma Corp changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 119 | 1 | 113 | −5 |
| Shares | 43.9M | 170.8K | 44.3M | +584.5K (+1.3%) |
| Value | $130.6M | $509.0K | $120.0M | −$10.1M (−7.8%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Arbutus Biopharma Corp at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 52,722 | $143.0K | 0.01% |
| Lazard Asset Management LLC | 23,536 | $63.0K | 0.00% |
| AQR Capital Management LLC | 19,430 | $53.0K | 0.00% |
| WMG Financial Advisors, LLC | 12,605 | $34.0K | 0.03% |
| Principal Financial Group Inc | 11,840 | $32.0K | 0.00% |
| Apollon Wealth Management, LLC | 11,600 | $31.0K | 0.00% |
| Verition Fund Management LLC | 10,411 | $28.0K | 0.00% |
| Price T Rowe Associates Inc | 10,083 | $27.0K | 0.00% |
| Financial Synergies Wealth Advisors, Inc. | 9,850 | $26.7K | 0.00% |
| Moneta Group Investment Advisors LLC | 9,225 | $25.0K | 0.00% |
| Aquatic Capital Management LLC | 2,100 | $6.00K | 0.00% |
| Lindbrook Capital, LLC | 565 | $2.00K | 0.00% |
| Point72 Hong Kong Ltd | 423 | $1.00K | 0.00% |
| Credit Suisse AG | 1 | $0 | 0.00% |
Sold out (19)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Centiva Capital, LP | 300,000 | $894.0K |
| Putnam Investments LLC | 142,677 | $425.0K |
| Two Sigma Investments, LP | 119,081 | $355.0K |
| Jump Financial, LLC | 57,300 | $171.0K |
| Jacobs Levy Equity Management, Inc | 55,713 | $166.0K |
| HRT Financial LP | 50,617 | $150.0K |
| Oracle Investment Management Inc | 50,000 | $149.0K |
| Verus Capital Partners, LLC | 28,600 | $72.0K |
| D. E. Shaw & Co., Inc. | 19,698 | $59.0K |
| Paloma Partners Management Co | 18,978 | $57.0K |
| Arete Wealth Advisors, LLC | 15,000 | $45.0K |
| Bayesian Capital Management, LP | 12,100 | $36.0K |
| Russell Investments Group, Ltd. | 4,120 | $12.0K |
| UBS Group AG | 1,298 | $4.00K |
| Glassman Wealth Services | 1,238 | $4.00K |
| Koshinski Asset Management, Inc. | 500 | $1.49K |
| FinTrust Capital Advisors, LLC | 30 | $0 |
| Ellevest, Inc. | 39 | $0 |
| Simon Quick Advisors, LLC | 100 | $0 |
Not filed for Q2 2022 yet (1)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 170,798 | $509.0K |